Parkinson’s Disease Market Size, Share, Competitive Landscape and Trend Analysis Report by Product and by Route of Administration : Global Opportunity Analysis and Industry Forecast, 2023-2032

Parkinson’s Disease Market Outlook 2027

Parkinson's disease is a brain disorder that leads to shaking, stiffness, and difficulty with walking, balance, and coordination. Parkinson's symptoms usually begin gradually and get worse over time. As the disease progresses, people may have difficulty in walking and talking. They may further experience mental &behavioral changes, sleep problems, depression, memory difficulties, and fatigue. Parkinson’s disease can be prevalent in both men and women. However, the disease affects about 50% more men than women. One clear risk factor for Parkinson's is age. Although most people with Parkinson’s first develop the disease at about age 60, about 5-10% of people with Parkinson's have "early-onset" disease, which begins before the age of 50. Early-onset forms of Parkinson's are often, but not always, inherited, and some forms have been linked to specific gene mutations.

COVID-19 scenarioanalysis

The major companies especially pharmaceutical and biotechnological came together with governments Pharmaceutical and biotechnological companies together with governments around the globe are working to combat with the COVID-19 outbreak, from supporting the development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are kept in the R&D pipeline in the coming years. Moreover, commonly used drugs such as hydroxychloroquine have seen huge boost in demand for the management of COVID-19. Increase in demand for drugs has been witnessed, which is likely to offer lucrative opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.

Top impacting factors:market scenario analysis, trends, drivers, and impact analysis

The major factor affecting the industry includesupsurge in the patient population.In addition, increase in geriatric population acts as a key growth driver of the global market, as aged individuals are highly susceptible to develop Parkinson’s disease.Furthermore, development of combination therapies for longer action of continuous dopaminergic stimulation drugs, neural transplantation, and gene therapy is expected to augment the market growth in the next coming years.

New product launches

Increase in focus over research and development such that the therapeutics become available to majority of population that are cost-efficient is expected to propel the Parkinson’s disease market growth in the coming years. For instance, in August 2019, FDA approved new add-on drug to treat off episodes in adults with Parkinson’s disease. The tablet named Nourianz (istradefylline) isas an add-on treatment to levodopa/carbidopa in adult patients with Parkinson’s disease experiencing "off" episodes. An "off" episode is a time when a patient’s medications are not working well, causing an increase in Parkinson’s diseasesymptoms, such as tremor and difficulty walking.

In April 2020, Neurocrine Biosciences, a San Diego-based medicine company, received Food and Drug Administration approval for a drug that makes a prominent Parkinson's disease treatment last longer. Patients in the U.S., though, wouldnot have access to the drug for at least another couple months, as Neurocrine intends to hold off any launch due to coronavirus-related concerns.

Surge in number of mergers and acquisitions

Increase in the number of mergers and acquisitions is anticipated toboost the industrygrowth in the coming years. For instance, in September 2020, Roche agreed to pay roughly $445 million for Inflazome, joining the race to introduce drugs that block the inflammasome, a part of the immune system linked to inflammatory diseases. The move will give the pharma company access to Inflazome’s entire pipeline, which includes two small molecules that have completed Phase I safety trials, Inzomelid and Somalix.

In October 2020, STADA Arzneimittel, the parent company of Thornton & Ross (T&R) and Reading-based Britannia Pharmaceuticals,strengthened its footprint in specialty pharmaceuticals by acquiring an innovative therapy used for treating late-stage Parkinson’s disease. The infusion of levodopa, carbidopa, and entacapone is already approved in Sweden, Denmark, Norway, and Finland, and STADA is currently submitting approval applications to launch the therapy in a number of major European markets. German-headquartered STADA is increasingly adding differentiated specialty pharmaceuticals to its existing strengths in generics and non-prescription consumer health products.

Key benefits of the report:

• This study presents the analytical depiction of the global Parkinson’s disease marketalong with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Parkinson’s disease market share.
• The current market is quantitatively analyzed to highlight the global Parkinson’s disease market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed Parkinson’s disease market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions answered in the global Parkinson’s disease market research report:

• Which are the leading players active in the global Parkinson’s disease market?
• What are the current trends that will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities of the market?
• What are the projections for the future that would help in tasking further strategic steps?

  Parkinson’s Disease Market Report Highlights

Aspects	Details
By Product	Monoamine Oxidase Inhibitors (MAOIs) Catechol-O-methyl transferase (COMT) Inhibitors Dopamine Agonists Peripheral Decarboxylase Inhibitors Levodopa combination therapy Others
By Route of Administration	Oral subcutaneous Transdermal Intestinal Infusion Others
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	Schwarz Pharma,, Acadia Pharmaceuticals,, AbbVie Inc., Pharma Two B Ltd, Boehringer Ingelheim GmbH, Novartis AG,, Sunovion Pharmaceuticals,, F. Hoffmann La Roche Ltd,, Abbvie Inc,, Medtronic Plc.